We want to save patients with severe cancer and autoimmune diseases

Clinical investigations with our lead antibody CAN04 to our proprietary target

Göran Forsberg, CEO

Safe Harbour Statement

The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia's current thinking with respect to future events and financial performance. Prospective statements only express the assessments and assumptions the company makes at the time of the presentation. These statements are well-considered, but the audience should note that, as with all prospective assessments, they are associated with risks and uncertainties.

Cantargia at a glance

- Specialized in antibody therapy/immunology, with initial focus on oncology
- Lead antibody CAN04 (nidanilimab) in clinical development, pathway clinically validated
- Platform around IL1RAP, lead candidate for autoimmunity and inflammatory disease 2019
- Granted IP - therapeutic target IL1RAP and CAN04
- Strong management team with proven track record in clinical development and business development
- Listed on Nasdaq Stockholm
- Approximately 5000 shareholders
- Based in Lund, Sweden

Financial highlights

- Share price: 15. 35 SEK (1.71 USD), Jan 18, 2019
- Market cap: 1016 MSEK (113 MUSD), Jan 18 2019
- Cash: 191 MSEK (21.3 MUSD), Sep 30 2018

Current owners (Sep 30, 2018)	
Sunstone	9.0%
1st AP fund	6.9%
Avanza Pension	5.2%
4th AP fund	4.6%
2nd AP fund	3.3%
Öhman Bank S.A.	3.3%
SEB S.A. clients	3.2%
Mats Invest AB	2.0%
Tibia konsult	1.9%
Kudu AB	1.9 %
Others	58.6%

Tumor inflammation – key to cancer features

Intrinsic pathway

Genome instability and mutation

Tumor-promoting inflammation

Extrinsic pathway

IL-1 blockade in cancer- validating clinical data

CANTOS trial (n=10061)

- Canakinumab (Novartis)
- Reduced lung cancer incidence by 67 % and death by 77 %.



- Clinical validation of IL-1 pathway
- Cantargia's CAN04 has broader MOA

Canakinumab phase 3 trials
(compl 20121/2022)

Adjuvant NSCLC (CANOPY-A)
After surgery, no mets, placebo control
1500 patients, recruitment ongoing

First line (CANOPY-1)
Untreated locally advanced/metastatic
Combination Pembro/Platinum doublet
627 patients

Second line metastatic (CANOPY-2)
Previously treated loc adv/metastatic
Combination Docetaxel
240 patients, recruitment ongoing

Source clinicaltrials.gov

CAN04 (nidanilimab) added value vs canakinumab









Canakinumab

- Antibody directed against one of the two IL-1 ligands, IL-1β

CAN04:

Double mechanism

- Binds the common signaling receptor and counteracts both ligands
- Induce killing via the immune system (ADCC)



CAN04 – CANFOUR clinical trial

Phase I/IIa trial - NSCLC and pancreatic cancer

- Jules Bordet, Brussels; Erasmus Rotterdam, NKI, Amsterdam; Rigshospitalet, Copenhagen; Radiumhospitalet, Oslo
- 22 patients treated:
  - Good safety up to 10 mg/kg
  - Significant effect on relevant biomarkers (IL-6, CRP)
  - 5/13 pts had stable disease up to 6 months
  - NSCLC, pancreatic cancer, colon cancer
- Phase IIa: focused on NSCLC and pancreatic cancer (appr 20 centres)
  - Monotherapy (appr 20 pat)
  - Combination with standard therapy (appr 30 pat per arm)
    - NSCLC Cisplatin/Gemcitabine
    - Pancreatic cancer Gemcitabine/nab-paclitaxel



Dec 2018

Early 2020

Details on www.clinicaltrials.gov

Targeting both tumor and endogenous IL1RAP allows synergistic effects with Cisplatin





10 mice per group

Cantargia

Significant value inflection points ahead of CANFOUR results

2019

- US regulatory and clinical strategy
- Clinical progress and initial phase IIa results
- Preclinical progress (immuno-oncology effects, combinations etc)
- CANxx progress

2020

- Phase IIa results

Cantargia summary

- Lead candidate antibody CAN04 in clinical trials against cancer
  - Encouraging phase I data, phase IIa initiated
  - Double mechanism of action
  - Initial development in NSCLC and pancreatic cancer (cancer forms with poor prognosis)
  - Direct effects on tumor cells and tumor microenvironment
  - Recent external validation of pathway
- Second generation antibodies for autoimmune disease
- Unique and strong IP
- Strong lead investors with high competence and well known track record
  - Funding through phase IIa - until mid 2020.